PMID: 16520665Mar 8, 2006Paper

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

Anti-cancer Drugs
Carlo L BelloKaren J Klamerus

Abstract

The effect of food on the oral bioavailability of sunitinib malate (SU11248, an oral, multi-targeted tyrosine kinase inhibitor with anti-angiogenic and anti-tumor activities) was assessed in a randomized open-label, two-way crossover study. A 50-mg dose of SU11248 was administered to 16 healthy subjects after a 10-h fast in one period and after a high-fat, high-calorie meal in the other period. The 90% confidence intervals (CIs) for maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) were within the 80-125% bioequivalence range, indicating the absence of a food effect. SU11248 exposure increased slightly in the fed compared with the fasted state (ratios of fed/fasted geometric least square means: Cmax 104%, AUC0-last and AUC0-infinity both 112%). There was a delay in the formation/absorption of the active metabolite SU12662 in the fed state (mean Cmax decreased 23%), but exposure remained unaffected (90% CIs for AUC0-last and AUC0-infinity were within 80-125%). These results indicate that SU11248 can be administered with or without food.

References

Dec 24, 2003·The Cancer Journal·Diane D Davey
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
Jan 14, 2005·Nature Reviews. Drug Discovery·Irena Melnikova, James Golden

❮ Previous
Next ❯

Citations

Dec 16, 2011·European Journal of Clinical Pharmacology·Meghan BrennanYingxue Cathy Liu
Aug 6, 2009·Cancer Chemotherapy and Pharmacology·George FountzilasMarios Marselos
Jan 6, 2010·Cancer Chemotherapy and Pharmacology·Carlo L BelloMelvin Toh
Sep 18, 2013·Cancer Chemotherapy and Pharmacology·Aiping ZhouJinwan Wang
Feb 16, 2008·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·S E RosenbaumM E Lacouture
Apr 25, 2009·International Journal of Clinical Oncology·Toshirou NishidaUNKNOWN Japanese Study Group on GIST
May 13, 2010·Investigational New Drugs·Yung-Jue BangAlberto Sobrero
Feb 4, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Bella PajaresEmilio Alba
Feb 14, 2012·Advances in Therapy·Sergio VázquezLuis Aparicio
Feb 20, 2013·Clinical Pharmacokinetics·Frederik E StuurmanJan H M Schellens
Jun 22, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven G DuboisSusan M Blaney
Jun 14, 2013·Clinical Medicine Insights. Oncology·Zhengyu WeiYuan Liu
Jun 7, 2014·European Journal of Medicinal Chemistry·Long ZhangChuanwen Fan
Jun 15, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nicolas WidmerAlain Astier
Jun 1, 2010·Cancer Chemotherapy and Pharmacology·Nielka P van ErpHans Gelderblom
Sep 24, 2008·Expert Opinion on Investigational Drugs·Bhanu K Vakkalanka, Ronald M Bukowski
Apr 18, 2013·Expert Opinion on Drug Metabolism & Toxicology·Savita BishtPeter Brossart
Oct 12, 2007·Expert Opinion on Pharmacotherapy·Brian I Rini
Jun 14, 2008·Expert Opinion on Investigational Drugs·Patricia M Lorusso, Joseph Paul Eder
May 21, 2009·Expert Opinion on Investigational Drugs·Hui K GanJennifer J Knox
Jul 20, 2010·Expert Opinion on Drug Metabolism & Toxicology·Marie-Paule SablinEric Raymond
Apr 26, 2006·Expert Opinion on Investigational Drugs·Robert J MotzerJames G Christensen
Sep 21, 2013·Expert Opinion on Investigational Drugs·Matias E Valsecchi, Takami Sato
Sep 28, 2013·Expert Opinion on Investigational Drugs·Umberto Leone Roberti MaggioreSimone Ferrero
Oct 14, 2014·Journal of Pharmaceutical Sciences·Jie ShaoGuohua An
Oct 15, 2009·Journal of Pharmaceutical Sciences·Kosalaram GotetiIftekhar Mahmood
Jul 24, 2015·Clinical Pharmacokinetics·Beatrix WulkersdorferMonika Schmid
Sep 14, 2010·Cancer Treatment Reviews·Heinz-Josef KlümpenHoward Gurney
Feb 6, 2010·Critical Reviews in Oncology/hematology·Cristina GrávalosJoan Manel Gasent
Sep 8, 2009·Cancer Treatment Reviews·Nielka P van ErpHenk-Jan Guchelaar
Apr 4, 2009·Clinica Chimica Acta; International Journal of Clinical Chemistry·Benoit BlanchetMichel Tod
Mar 14, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S GeorgeG D Demetri
Jul 28, 2007·Pharmacotherapy·Cheryl A Grandinetti, Barry R Goldspiel
Mar 21, 2016·Drug Discovery Today·Annelieke E C A B WillemsenNielka P van Erp
Aug 20, 2014·Asia-Pacific Journal of Clinical Oncology·Alison Zhang, Howard Gurney
Sep 26, 2009·Journal of Clinical Pharmacology·Reza KhosravanCarlo L Bello

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.